News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,441 Results
Type
Article (13557)
Company Profile (110)
Press Release (246774)
Section
Business (87930)
Career Advice (461)
Deals (15323)
Drug Delivery (63)
Drug Development (36520)
Employer Resources (49)
FDA (6259)
Job Trends (6182)
News (150001)
Policy (14005)
Tag
Academia (435)
Alliances (23071)
Alzheimer's disease (346)
Approvals (6248)
Artificial intelligence (55)
Bankruptcy (143)
Best Places to Work (4296)
Biosimilars (37)
Biotechnology (44)
Breast cancer (37)
Cancer (273)
Career advice (404)
Cell therapy (37)
Clinical research (30295)
Collaboration (123)
Compensation (55)
COVID-19 (746)
C-suite (39)
Data (267)
Diabetes (45)
Diagnostics (1228)
Drug pricing (56)
Earnings (31311)
Employer resources (43)
Events (36563)
Executive appointments (138)
FDA (6416)
Funding (86)
Gene therapy (57)
GLP-1 (284)
Government (1262)
Healthcare (3516)
Infectious disease (762)
Inflammatory bowel disease (45)
Interviews (58)
IPO (5803)
Job creations (2048)
Job search strategy (372)
Layoffs (166)
Legal (3407)
Lung cancer (42)
Manufacturing (81)
Medical device (1259)
Medtech (1261)
Mergers & acquisitions (9525)
Metabolic disorders (147)
Neuroscience (434)
NextGen Class of 2024 (1580)
Non-profit (589)
Northern California (365)
Obesity (92)
Opinion (108)
Patents (50)
People (28381)
Pharmaceutical (64)
Phase I (7877)
Phase II (12809)
Phase III (11514)
Pipeline (90)
Podcasts (38)
Policy (43)
Postmarket research (1399)
Preclinical (3156)
Radiopharmaceuticals (116)
Rare diseases (75)
Real estate (2629)
Regulatory (9794)
Research institute (562)
Resumes & cover letters (55)
Southern California (371)
Startups (1624)
United States (3666)
Vaccines (107)
Weight loss (74)
Date
Today (33)
Last 7 days (246)
Last 30 days (919)
Last 365 days (12758)
2024 (10798)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14886)
2018 (11713)
2017 (13889)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (312)
Arizona (38)
Asia (19739)
Australia (2550)
California (845)
Canada (546)
China (95)
Connecticut (36)
Europe (38660)
Florida (119)
Illinois (95)
Indiana (78)
Kansas (50)
Maryland (136)
Massachusetts (742)
Minnesota (47)
New Jersey (361)
New York (241)
North Carolina (263)
Northern California (365)
Ohio (35)
Pennsylvania (249)
South America (498)
Southern California (371)
Texas (111)
Washington State (63)
260,441 Results for "saptalis pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
Appili Therapeutics Inc. announced today it has amended its agreement with Saptalis Pharmaceuticals LLC o expand the territories in which Saptalis will commercialize ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole.
February 8, 2022
·
5 min read
FDA
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
Appili Therapeutics Inc. today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from the U.S. Food and Drug Administration (“FDA”) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501).
September 25, 2023
·
5 min read
Business
Fennec Pharmaceuticals Announces Management Change
Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.
July 1, 2024
·
4 min read
Deals
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.
April 29, 2024
·
10 min read
Press Releases
Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals
October 28, 2024
·
9 min read
BioMidwest
Aurorium Launches Haelium™ Pharmaceutical Solutions
Aurorium, a specialty ingredients manufacturer and materials innovation partner, is pleased to announce the launch of Haelium™ Pharmaceutical Solutions.
June 25, 2024
·
2 min read
Press Releases
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 29, 2024
·
7 min read
Press Releases
Acella Pharmaceuticals, LLC, an Alora Pharmaceuticals, LLC Subsidiary, Partners with Paloma Health for Hypothyroidism Patients
October 23, 2024
·
2 min read
Deals
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
Cycle Pharmaceuticals Ltd today confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda’s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million.
June 6, 2024
·
5 min read
Biotech Bay
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
NovaBay® Pharmaceuticals, Inc. and Eyenovia, Inc. have commenced activities under a previously announced co-promotion agreement.
July 1, 2024
·
8 min read
1 of 26,045
Next